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Because of the liver graft's ability to resist cytotoxic 
antibody-mediated rejection, it has become dogma that 
the conventional transplant crossmatch used to avoid 
hyperacute rejection of other organs is irrelevant to the 
liver. We examined this hypothesis in a consecutive 
series of adult primary liver recipients treated with 
FK506 and low-dose steroids. 
Twenty-five of 231 (10.8%) patients received a liver 
from a cytotoxic-positive crossmatch donor (more than 
50% of donor T lymphocytes were killed by dithiothre-
itol-pretreated recipient serum). The outcome was com-
pared with that of 50 negative crossmatch patients who 
had their transplantations just before and after the 
crossmatch positive cases. 
The one-year graft and patient survivals were 56% 
and 68%, for positive and 82% and 86% for negative 
crossmatch patients (P=0.004, P=0.03, respectively). 
The difference between patient and first graft survival 
was accounted for by retransplantation, which was 4 
times more frequent in the positive-crossmatch cases. 
Histologically, failed allografts obtained at the time of 
retransplantation revealed a spectrum of pathologic 
findings related to vascular injury. 
This study showed a higher difficulty of intraopera-
tive blood product management, a degraded prognosis, 
and a poorer average quality of ultimate graft function 
when liver transplantation was performed against pos-
itive cytotoxic crossmatches. In such patients for whom 
crossmatch-negative donors may never be found because 
of the broad extent and intensity of sensitization, special 
therapeutic strategies perioperatively must be evolved 
if results are to improve. 
The immune response to hepatic transplants has previously 
been described as a cellular rejection response (1). We have 
reported that human hepatic transplants are unusually resist-
ant to antibody-mediated rejection, and can be successfully 
performed in the face of positive antidonor crossmatches, as 
detected by the standard complement-dependent cytotoxicity 
test (2-4). 
It is true, however, that crossmatch-positive hepatic grafts 
have been lost repeatedly for inadequately explained reasons 
1 Presented at the 17th Annual Meeting of the American Society of 
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at our center and elsewhere (5-9). Experienced liver transplant 
surgeons speak of some patients as "liver-eaters" and there are 
case reports from several institutions describing hyperacute 
rejection of a liver allograft. This syndrome tends to be asso-
ciated with a positive cytotoxic crossmatch, but not invariably 
(8). 
There are many theoretical explanations for the liver graft's 
ability to resist cytotoxic antibody. These include: (a) release 
of soluble class I histocompatibility (HLA) antigens into the 
circulation, which presumably bind the preformed lymphocy-
totoxic antibodies, preventing their destructive effects; (b) 
Kupffer cell binding of preformed antibodies or immune com-
plexes; (c) the unique sinusoidal microvasculature, and (d) a 
dual afferent blood supply that presumably protects the organ 
from ischemic damage (1, 10-13). 
In this study, we have reexamined the extent to which the 
liver is able to resist cytotoxic antibody-mediated rejection in 
a consecutive series of adult primary liver recipients treated 
with FK506 and low-dose steroid therapy. The sera were pre-
treated with dithiothreitol before the T lymphocyte cross-
matching and pretreatment panel screening for panel reactive 
antibodies. 
MATERIALS AND METHODS 
Between November 31, 1989 and September 9, 1990, 243 adult 
patients (16 years old or older) received their first orthotopic liver 
transplantation under FK506 and low-dose steroid therapy at the 
University Health Center of Pittsburgh. 
In this period, 25 consecutive patients received a liver from a cyto-
toxic positive-crossmatch donor (more than 50% of donor lymphocytes 
were killed by dithiothreitol pretreated recipient serum). The cross-
match test was considered negative when less than 10% of cells were 
killed. When 11-50% of donor lymphocytes were killed by recipient 
serum, the crossmatch was interpreted as doubtfully or weakly positive. 
None of the 243 patients received ABO blood group-incompatible 
grafts and 12 patients were excluded because they were not tested for 
Iymphocytotoxic antibody against a specific donor with DTT treat-
ment. 
There was a generally high degree of illness in both the positive 
crossmatch group and their controls, as defined by the current United 
Network for Organ Sharing (UNOS) stratification: status I-at home, 
functioning without nursing care; status 2-at home, not working and 
requiring professional nursing care; status 3-hospital-bound; status 
4-ICU-bound; UNOS stat-ICU-bound on life support (14). 
The outcome was compared between the crossmatch-positive grafts 
and that of 50 negative grafts with matched UN OS urgency score who 
had their transplantations just before and after the crossmatch-positive 
cases. 3 Address requests for reprints to Thomas E. Starzl, M.D., Ph.D., 
Department of Surgery, 5C Falk Clinic, 3601 Fifth Ave., Pittsburgh, 
PA 15213. 
Cross match test. Pretransplant sera was drawn immediately before 
liver transplantation and used for the crossmatching. All sera were 
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dithiothreitol-treated to inactivate IgM as described earlier (15). The 
donor T lymphocytes were isolated from lymph nodes using CD3-
conjugated dynabeads (Dynal, Inc., Great Neck, NY). 
The lymphocyte cytotoxicity test was performed according to NIH 
standards with one washing. Briefly, 1,,1 of 2x106/ml T lymphocytes 
were added to 1 "I of serum, which was 2-fold diluted up to 1:8 using 
RPMI 1640 solution, for 1 hr at room temperature. After one washing, 
5 "I of rabbit complement was added for an additional 1 hr at room 
temperature and trypan blue was added to stain dead cells. 
ImmUllOSuppression. Intravenous doses of 0.1 mg/kg of FK506 were 
infused over 24 hr, starting in the operating room, and repeated every 
24 hr until oral intake began. The conversion from intravenous to oral 
doses of 0.15 mg/kg every 12 hr was overlapped for one day. 
In this period, 1 g intravenous methylprednisolone was given to 8 of 
25 positive-crossmatch patients (32%) and 11 of 50 negative-cross-
match patients (22%) after reperfusion of the liver allograft. A daily 
dose of 20 mg methylprednisolone was started in all patients. 
Rejection episodes that were unresponsive to increasing the main-
tenance doses of FK506 were treated with a single 19 bolus of methyl-
prednisolone. If rejection persisted, the patient received an additional 
5-day burst of methylprednisolone or a 3-5-day course of 5-10 mg/day 
ofOKT3. 
Organ preservation. All of the liver allografts in this study were 
preserved with the University of Wisconsin solution. 
Graft survival, follow-up, and statistics. The survival rates were 
calculated by the method of Kaplan-Meier. The results were summa-
rized as of April 30, 1991, with a median follow up of 12 months and a 
minimum follow up of 6 months. 
Statistical comparisons were made by the generalized Wilcoxon 
method, by Student's t test and by chi-square analysis. The difference 
was considered statistically significant when P<0.05. Data are shown 
as mean values ±SE. 
RESULTS 
The incidence of positive crossmatch. Of the 231 patients who 
had a donor lymphocytotoxic crossmatch test, it was positive 
against donor in 25 (10.8%) recipients, weakly or doubtfully 
positive in 10 (4.3%) recipients, and negative in 196 (84.8%) 
recipients. 
Of the 25 cases with positive crossmatch recipients, 18 
(72.0%) had panel-reactive antibodies of greater than 40%, 
which were pretreated by DIT. Seven patients had a PRA of 
less than 40%. 
Table 1 shows the circumstances of 25 crossmatch-positive 
patients (positive-crossmatch group) and 50 crossmatch-nega-
tive patients (negative-crossmatch group). 
The cold ischemic times of liver grafts in both groups were 
not statistically significantly different: 15.7±0.9 hr (range 7.3-
27.0 hr) in the positive-crossmatch group and 14.8±0.7 hr 
(range 4.3-27.2 hr) in the negative-crossmatch group. 
Survival. The graft survival of first hepatic allografts was 
compared in 25 positive crossmatch patients and 50 negative 
patients (Fig. 1). There was a statistically significant difference 
in the survival curves between the two groups (P=0.OO4 by 
generalized Wilcoxon method). The one-year graft survival was 
56% for positive-crossmatch patients and it was 82% for neg-
ative-crossmatch patients. 
Eleven of 25 positive-crossmatch grafts (44% ) failed for 
various reasons (Table 2). The median graft survival of those 
11 failed grafts was 14 days (range: 1 day to 245 days). 
Six crossmatch-positive patients (24%) were retransplanted 
at an interval of 1-125 days, and 3 of them are still alive. On 
the other hand, in the negative-crossmatch group, retransplan-
tation of the liver was done in 3 of 50 patients (6%). 
TABLE 1. Cases of positive and negative crossmatches 
Crossmatch Positive Negative P 
Number of patients 25 50 
Age (mean + SE) 51.9 ± 1.7 45.4 ± 2.0 ns 
Male/female 11/14 28/22 ns 
UNOS score 3.7 ± 0.11 3.7 ± 0.08 ns 
CIT (hr) 15.7 ± 0.9 14.8 ± 0.7 ns 
PRA(%) (mean + SE) 69.4 ± 5.4 2.5 ± 1.6 <0.001 
Original disease 
Nonalcoholic cirrhosis 11 17 ns 
Alcoholic cirrhosis 7 18 ns 
Cholestatic disease 7 9 ns 
Hepatoma 0 3 ns 
Fulminant hepatic failure 0 3 ns 
• UNOS: United Network for Organ Sharing; CIT: cold ischemic 
time; PRA: panel-reactive antibody. 
GRAFT SURVIVAL(%) 
lMM~----------------------------------------~ 
60 _ ................... _ .. _ ........................ . 
40 _ .......................... "., ............... . 
p<O.005 
20 .. " .. ....·,,·.·,,_ .. ~ ... __ .... · ... ·." ...... ' ... ".h •.• h._ .. _" ..................... "' ......... m .... _ ........ _ .............. "' ................. _ .......... .. 
f~ ~b~;Kel 
M4-~~~~~~~~~-i-i-i-i~ 
o 2 5 6 7 8 9 10 11 12 17 
MONTHS 
FIGURE 1. The actuarial graft survival rates in 25 adults positive-
crossmatch patients and 50 negative-crossmatch patients. 
TABLE 2. Outcome of 25 positive and 50 negative crossmatch 
patients 
ClO6smatch test 
Positive Negative 
Starting number of patients 25 50 
Retransplantation 6 3 
Death 8 7 
Total graft loss 11 9 
Clinical cause of graft loss: 
Primary nonfunction 1 1 
Hepatic arterial thrombosis 3 1 
Portal vein thrombosis 0 1 
Biliary complication 2 0 
Acute cellular rejection 0 1 
Sepsis 2 3 
Mycotic aneurysm 1 0 
Recurrent hepatitis 0 1 
Postoperative bleeding 1 0 
GI bleeding" 1 0 
Recurrence of malignancy 0 1 
• GI: gastrointestinal. 
The patient survival was also significantly different in posi-
tive-crossmatch (68%) and negative-crossmatch patients (86%) 
(P=0.03). The difference between the first graft and patient 
survival were accounted for by the incidence of retransplanta-
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tion, which was four times more frequent (24% versus 6%) in 
the positive-crossmatch cases than in the negative-crossmatch 
patients. 
The cause of graft failure at the time of retransplantation. In 
the positive-crossmatch group, all of 6 failed grafts that required 
retransplantation had strong positive-crossmatch donors (more 
than 80% killing of donor lymphocytes) with more than 70% 
PRA. The pathological findings showed a widespread coagula-
tive necrosis with intrahepatic venular thrombi in one graft, 
although the cold ischemic time was less than 8 hr. This graft 
failed on the operating room table and had to be immediately 
replaced. Two grafts had hepatic arterial thrombosis, in one 
case with severe acute cellular rejection with prominent neu-
trophilia. One graft had severe cholangitis with focal intrahe-
patic thrombi and infarcts. Another two grafts failed because 
of biliary tract problems accompanied by intrahepatic bile duct 
necrosis with intrahepatic arterial thrombi. Five of 6 failed 
grafts occurred when vascular problems were the cause of 
retransplantation. 
In the negative-crossmatch group, three grafts required re-
transplantation for portal vein thrombosis, arterial graft throm-
bosis and acute cellular rejection (one case each). 
Panel-reactive antibody (PRA). The graft survival of cross-
match -positive allografts with high PRA titers (more than 40%) 
was 44.4%, while it was 85.7% when the PRA titers were less 
than 40%. There was no statistically significant difference 
(P=0.07) because the number of crossmatch-positive grafts was 
small. However, there was a tendency toward decreased graft 
survival when the PRA titer was higher than 40% (Fig. 3). 
Intraoperative blood usage. Intraoperative blood product 
usage differed significantly in these two groups (Fig. 4). The 
packed red blood cell usage in crossmatch positive versus neg-
ative recipients was 35.6 units versus 15.1 units (P<0.005). 
Platelet usage was 25.7 units versus 10.4 units, respectively 
(P<0.005). Fresh frozen plasma usage was 32.8 units in cross-
match-positive patients and 15.1 units in crossmatch-negative 
recipients (P<0.005). 
Postoperative platelets usage was significantly higher in 
crossmatch-positive recipients than in crossmatch-negative pa-
tients-45.1 units/patient vs. 11.0 units/patient (P<O.OOl) dur-
ing the first postoperative week. 
Postoperative liver function. Postoperative liver function tests 
were done in these two groups. Seventeen crossmatch-positive 
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FIGURE 2. The actuarial patient survival rates in 25 adult positive-
crossmatch and 50 negative-cross match patients. 
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FIGURE 3. Actuarial graft survival rates for 18 patients whose PRA 
were 2:40% and 7 patients whose PRA were <40%, with DTT treatment 
sera in positive-crossmatch patients. 
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FIGURE 4. Blood usage in positive· and negative-crossmatch pa-
tients. (PRBC) packed red blood cells; (FFP) fresh frozen plasma; 
(CRYO) cryoprecipitated plasma; (POST OP PLATELETS) postop-
erative usage of platelets. Mean ± SE is shown. 
patients and 47 negative patients who survived more than one 
month were studied. The preoperative total bilirubin in these 
two groups was not statistically significantly different. 
During the first 3 weeks after liver transplantation, the total 
bilirubin in the positive-crossmatch patients was significantly 
higher than that of the negative crossmatch patients (Fig. 5). 
Even at postoperative day 60, the total bilirubin of crossmatch-
positive patients was still significantly higher than that of 
crossmatch-negative patients (2.32±0.88 versus 0.98±0.1O mg/ 
dl, P<0.025). 
Alkaline phosphatase levels in positive-crossmatch patients 
tended to be higher postoperatively when compared with those 
of crossmatch-negative patients. But a significant difference 
(P<0.05) was found only on postoperative day 90 (Fig. 6). 
The postoperative platelet count in the crossmatch-positive 
patients was significantly lower than that of crossmatch-nega-
tive patients (Fig. 7), and the crossmatch·positive group re-
quired a significantly greater number of postoperative platelet 
transfusions (45.1 units vs. 11.0 units, P<O.OOl). 
-_._. __ ._ .. _---------_._----
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FIGURE 5. Serum total bilirubin levels after liver transplantation in 
positive- (n=17) and negative- (n=47) crossmatch patients who were 
followed for more than one month (mean ± SE). There was a significant 
elevation in total bilirubin levels in crossmatch-positive patients. 
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FIGURE 6. Serum alkaline-phosphatase levels after liver transpian-
tation in positive- (n=17J and negative-crossmatch patients (n=47) 
who were followed for more than one month. Mean ± SE is shown. 
OKT3 administration. OKT3 was administered to 11 of 25 
positive-crossmatch patients. Four patients received this drug 
prophylactically, and 7 patients were treated for biopsy-proved 
rejection. 
Three of 4 grafts in the prophylactic group failed, while 
rejection was successfully treated in 6 of 7 livers with biopsy-
proved rejection (Fig. 8). One patient required retransplanta-
tion at 3 months for multiple intrahepatic biliary strictures. 
DISCUSSION 
Our previous study evaluating patients treated with cyclo-
sporine and steroids demonstrated that antidonor lymphocy-
totoxic antibody (a positive crossmatch) adversely affected the 
survivals of primary hepatic allografts during the first 6 months 
after liver transplantation (16). The reason appears to be 
immunological, as the grafts were lost to rejection significantly 
more often in positive-crossmatch than in negative-crossmatch 
transplantations. One of the limitations of the previous report 
was that DTT pretreatment was not employed. 
Since November 1989 we have adopted the antidonor T 
lymphocytotoxic antibody assay with DTT treatment of recip-
ient sera. DTT dissects the disulfide bond and reduces the 
activities of IgM antibodies and is useful in distinguishing a 
false-positive crossmatch (from IgM antibodies) from true sen-
sitization due to IgG antibody (15, 17). 
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FIGURE 7. The platelet count before and after liver transplantation 
in positive- (n=17) and negative-crossmatch patients (n=47) who were 
followed for more than one month. Mean ± SE is shown. The platelet 
counts in positive-crossmatch patients were significantly lower than 
those of crossmatch-negative patients. 
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FIGURE 8. Total bilirubin levels before and after OKT3 treatment 
in crossmatch-positive patients. The OKT3 was administered at the 
time of biopsy-proved rejection (n=7J. 
Hyperacute rejection of renal allografts is mediated by donor-
specific lymphocytotoxic antibodies directed primarily against 
vascular endothelium (18). Within from minutes to hours of 
revascularization, complement activation by alloantibodies 
causes microvascular occlusion by platelet and fibrin aggre-
gates, infiltration of neutrophils and mononuclear cells, and 
endothelial destruction (19-20). 
In contrast to kidneys and hearts, the liver is relatively 
resistant to antibody-mediated rejection in experimental ani-
mals (21) and humans (4, 22). While not invulnerable to 
humoral rejection, the liver's relative resistance to this process 
is not fully understood. The liver graft may neutralize existing 
antibodies by Kupffer cell action (23-24), by the secretion of 
soluble class I MHC antigens that neutralize or alter the 
antibodies (13, 25-26) and/or by poor expression of class I 
antigens on hepatocytes (27-28). The dual blood supply is also 
advantageous as the microvascular thrombosis and intense 
vasoconstriction associated with humoral events only develop 
in the arterial tree. In addition, the enormous mass of the liver 
may offer protection against antibody-mediated graft destruc-
tion. 
Classic hyperacute renal allograft rejection brings about the 
destruction of the graft within 24 hr. This type of biological 
event is extremely rare in liver transplantation, but antibody-
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mediated events can cause graft loss over days to weeks. Fur-
thermore, sensitized patients may have grave problems with 
both acute and chronic cellular rejection as we have previously 
reported (16). 
The pathologic findings in biopsy specimens and failed allo-
grafts in this series of patients will be described in detail 
elsewhere.4 Immediately after reperfusion, crossmatch-positive 
grafts often contained platelet aggregates in the veins and 
sinusoids, although hemorrhagic congestion like that seen with 
ABO-incompatible grafts was not generally observed. Further-
more, patients with a positive crossmatch underwent liver 
biopsy more often, especially in the first 10 days, and demon-
strated a higher incidence of cellular rejection and histopatho-
logic changes of "preservation" in ischemic injury. This oc-
curred despite no observable difference in the cold ischemic 
trial. 
In summary, a range of pathologic findings were observed, 
but these had a common ba~is of presumed ischemic damage, 
with the differences being due to the severity and acuteness of 
ischemia. In this regard, recent experimental animal studies 
have shown that the timing, type, and eventual outcome of 
sensitized animals directly correlated with the titer antigraft 
antibodies (Nakamura, Murase, Demetris et al., manuscript in 
preparation) . 
In view of the heterogenous pathologic findings, it was not 
surprising that the causes of graft failure in the positive-
crossmatch patients also were variable. The allograft of one 
patient who had a strong positive crossmatch with a 97% PRA 
had widespread coagulative necrosis with intrahepatic venular 
thrombi immediately after transplant and required immediate 
retransplantation. Three other failed grafts had hepatic arterial 
thrombosis. One of them was accompanied by severe, predom-
inantly neutrophilic and lymphoblastic, portal infiltration. Two 
grafts failed due to biliary complications related to the hepatic 
arterial blood supply. 
The indications for retransplantation were often related to 
vascular problems. These findings suggest ischemic insult to 
the hepatic lobule at the major arterial component-the arte-
riolar or sinusoidal levels. This feature was also seen in arterio-
grams of liver allograft recipients within days after liver trans-
plantation. Presumably, the sinusoidal endothelium and the 
terminal hepatic vessels are the target for antibody- and com-
plement-mediated injury of the allograft in positive-crossmatch 
recipients. This injury may lead to endothelial swelling with 
platelet and granulocyte trapping, and resultant hypoperfusion 
ofthe hepatic lobule and/or intrahepatic bile duct necrosis. 
Intraoperative monitoring by thromboelastogram in the last 
five years has reduced blood infusion volume by 33% and has 
increased blood coagulation stability without adding blood 
products (30). Also, the appropriate use of epsilon-aminoca-
proic acid in patients undergoing liver transplantation is very 
effective in treating fibrinolysis and associated generalized 
oozing (29, 30). Despite these advances, this study showed 
more difficulty in intraoperative blood product management in 
positive-crossmatch recipients. 
The platelet counts prior to liver transplantation were not 
significantly different in the groups. The intraoperative platelet 
usage was significantly higher in positive-crossmatch patients 
during liver transplantation. Furthermore, postoperative plate-
4 Nakamura K, Yagihashi A, Iwaki Y, et al. A clinicopathologic study 
of human liver allograft recipients harboring preformed IgG lympho-
cytotoxic antibodies. (Submitted for publication.) 
let usage by positive-crossmatch patients was significantly 
higher than that of negative patients. 
The fact that many of the crossmatch positive patients were 
highly sensitized may playa significant role in platelet trans-
fusion requirements, as it is well known that platelets express 
class I antigens (31, 32), and specific alloimmunization ofthese 
antigens is a major cause of refractoriness in the thrombocy-
topenic patients to platelet transfusion (33, 34). Furthermore, 
the liver plays a key role in removal of platelet aggregates and 
immune complexes (24). Recently, crossmatching with platelet 
targets in renal transplants has been reported and it may be 
helpful to avoid early primary nonfunction while minimizing 
false-positive reactions of lymphocytotoxic crossmatches (35). 
Following the development of FK506 (9, 36), the recent rate 
of early retransplantation has been reduced to 12.7% in adults 
(36). However, the retransplant rate in positive-crossmatch 
patients was observed to be extremely high (24%). Thus ad-
vances in immunosuppression added to improvements in sur-
gical techniques, organ preservation, and perioperative care 
have allowed us to demonstrate the adverse impact on liver 
transplantation of the positive cytotoxic crossmatch state. How 
this information will affect management strategy is being stud-
ied. 
We still advocate liver transplantation for desperately ill 
patients with high PRAs and do not discriminate against their 
selection on a serologic basis. We routinely obtain PRAs in all 
recipients prospectively in order to identify the high-risk recip-
ient population. We now perform the crossmatch test whenever 
the donor lymphocyte preparations are ready so that the results 
are known before transplanting the liver. In case of a positive 
crossmatch, prophylactic high-dose steroids are begun in the 
operating room and continued for at least five days. OKT3 is 
started either prophylactically or subsequently at the slightest 
suspicion of rejection. 
Conclusion. These data showed more difficulty in intraoper-
ative blood product management, a degraded prognosis, and a 
poorer average quality of ultimate graft function when liver 
transplantation was performed against a positive cytotoxic 
crossmatch. In such patients, for whom crossmatch-negative 
donors may never be found because of the broad extent and 
intensity of sensitization, special therapeutic strategies periop-
eratively must be evolved if results are to improve. 
ORAL DISCUSSION 
DR. SHAW (Omaha, Nebraska): Who are these patients? 
That is, how have you selected this group of 25 patients from 
500 or 600 liver transplants performed at Pittsburgh yearly? 
How did you choose your control patients for comparison? Fifty 
control patients from a group of how many? 
DR. BRONSTHER: In November of 1989 we started doing 
DTT crossmatching. So from that time forward we began 
accruing patients. They're a consecutive series of patients. We 
stopped adding patients in September of 1990 so we had some 
follow-up. The controls were UNOS-matched patients imme-
diately preceding and immediately following the crossmatch-
positive recipient. 
DR. SHAW: Did you also control for UNOS status? How? 
Would you merely go to the next patient until you found one 
with the same UNOS status? 
DR. BRONSTHER: Right, we thought that would be the 
best way. There was a high degree of urgency. The average 
UNOS status was 3.7. 
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DR. SHAW: And of all your recipients, you only had 25 
positive-crossmatch patients with that technique? 
DR. BRONSTHER: What we have is what's reported. Ap-
proximately 10% of our patients, 10.8% of this series, was 
crossmatch-positive. Those are the same numbers you'll find 
in almost any series. The numbers are slightly lower because if 
you don't do DTT treatment you'll have about a 1O-20-percent 
false-positive or falsely higher incidence of positive-cross match 
patients. 
DR. ASCHER (San Francisco, California): You state that 
you have a UNOS status-matched control population, and that 
there was a high degree of urgency in both populations. Yet 
your results in the negative patients are really quite good. Might 
this suggest that the UNOS classification did not correlate with 
survival? 
The second question relates to the patients who had positive 
crossmatches yet survived. We've heard so much about shed 
antigen from the liver. I was wondering if you have looked up 
those patients who survived in spite of a positive crossmatch. 
Can you correlate survival with shed antigen or the develop-
ment of antiidiotypic antibodies? 
DR. BRONSTHER: We haven't looked at shed antigen 
specifically. What we do know is that in the group of patients 
who survived, the positive crossmatch usually disappears early 
in the postoperative course. 
DR. ASCHER: Do you want to address the first issue of your 
gravely ill patients with outstanding survival? 
DR. BRONSTHER: Well, I'm not sure that's the topic of 
this talk, but what I think you're noting is the improved graft 
survival across the board in our patients treated with FK506. 
In selected groups of good-risk patients, our one-year patient 
and graft survivals are over 92%. What you see here in fact 
reflects results with our high-risk patients, about a 10% decre-
ment in survival. FK506 is a good drug. 
DR. TEPERMAN (New York, New York): Your results are 
certainly different than observations prior to FK506. Is it 
possible that the steroid-sparing effect, or the way FK506 is 
being used, might be responsible? If more steroids were used, 
do you think the results would be similar? 
DR. BRONSTHER: We're investigating those issues. The 
way we currently manage crossmatch-positive patients includes 
a standard five-day steroid-taper. Prostaglandin administration 
has been part of our efforts to address the possible vasocon-
striction associated with positive crossmatches. We may have 
unveiled some underlying biological phenomena specific to the 
liver by reducing steroids in this group of patients. 
DR. R. SHEIL (Australia): This is indeed a remarkable 
change of course for the Pittsburgh group. We happen to agree 
with your findings and have been promulgating this for some 
time now. What you're saying, though, is that an immunological 
event, such as the positive crossmatch, is then followed in your 
series by a significant complication rate that doesn't really 
seem to be immunological. I think that you were trying to relate 
the two, and I'd like you to comment on that. 
DR. BRONSTHER: I believe most of our observations have 
in fact been immunological in origin. The pathology of these 
patients and the controls have been analyzed separately, but 
the primary finding was microvascular thrombosis. 
We have lost some grafts. One of the grafts was lost on the 
table; classic IgG, IgM, and complement degradation products 
were identified on that graft. Although it is rare to lose a liver 
graft to hyperacute rejection, I do think antibody-mediated 
phenomena over the course of days to weeks does impact even 
on liver grafts. 
DR. SHEIL: Well, our graft losses did include three fairly 
fulminating-type rejections within a few days of transplant. We 
have now done what you've suggested and altered our prepa-
ration of these patients; people with broadly crossreactive an-
tibodies are now prepared by plasmapheresis. At the time of 
transplant we've been removing the spleen. We have only done 
this three times; all patients are alive. 
DR. WIESNER (Rochester, Minnesota): I was interested by 
your late rise in alkaline phosphatase levels. We have shown 
that a positive crossmatch is associated with ductopenic rejec-
tion. I was wondering whether you have made similar obser-
vations? 
DR. BRONSTHER: We have seen a phenomenon similar to 
what you described. We believe these findings are secondary to 
microvascular ischemic injury. 
DR. BELZER (Madison, Wisconsin): How many of your 
patients with broadly reacting antibodies had specific antibod-
ies against an antigen of the donor? In other words, two types 
of patients may have high PRAs-those that react against 
everybody, or those patients who have a specific antibody, for 
example against the A2 specificity. They will react against half 
the population in the United States because half have the A2 
antigen. So, how many of your patients had specific antibodies 
against an antigen that was present on the donor liver? 
DR. BRONSTHER: All 25 patients had a positive cross-
match specifically against the donor antigen; 72% of the pa-
tients had PRAs that were greater than 40%. However, I do 
not know the direct answer to your question. 
DR. BELZER: I think you should go back and see how many 
of those patients had a specific antibody, and whether the 
antibody was shared by the donor. 
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